연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
2265. ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines.
Liu J1, Hong J1,2,3, Ahn KS4, Go J4, Han H1, Park J1, Kim D1, Park H1, Koh Y1,2,3, Shin DY1,2,3, Yoon SS1,2,3.
Leuk Lymphoma. 2019 Oct;60(10):2532-2540. doi: 10.1080/10428194.2019.1594211. Epub 2019 Apr 5.
Link
2264. Truncation of MYH8 tail in AML: a Novel prognostic marker with increase cell migration and epithelial-mesenchymal transition utilizing RAF/MAPK pathway.
Park H1, Kim D1, Kim D1, Park J1, Koh Y2, Yoon SS1,2.
Carcinogenesis. 2019 Aug 20. pii: bgz146. doi: 10.1093/carcin/bgz146. [Epub ahead of print]
Link
2263. The upregulation of Pim kinases is essential in coordinating the survival, proliferation, and migration of KIT D816V-mutated neoplastic mast cells.
Park H1, Kim D1, Koh Y2, Yoon SS3.
Leuk Res. 2019 Aug;83:106166. doi: 10.1016/j.leukres.2019.106166. Epub 2019 Jun 12.
Link
2262. Interpretation of EBV infection in pan-cancer genome considering viral life cycle: LiEB (Life cycle of Epstein-Barr virus).
Song H1,2, Lim Y3, Im H4, Bae JM5, Kang GH5, Ahn J6,7, Baek D6,7, Kim TY3, Yoon SS8,9, Koh Y10,11.
Sci Rep. 2019 Mar 5;9(1):3465. doi: 10.1038/s41598-019-39706-0.
Link
2261. Early closure of a Phase I clinical trial for SABR in early-stage glottic cancer
Kang BH, Yu T, Kim JH, Park JM, Kim JI, Chung EJ, Kwon SK, Kim JH, Wu HG
Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):104-109
Link
2260. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer.
Wang S1, Oh DY2, Leventaki V3, Drakos E4, Zhang R5, Sahin AA6, Resetkova E6, Edgerton ME6, Wu W7, Claret FX8.
Cancer Lett. 2019 Nov 28;465:12-23. doi: 10.1016/j.canlet.2019.08.016. Epub 2019 Aug 29.
Link
2259. ATM in DNA repair in cancer.
Jin MH1, Oh DY2.
Pharmacol Ther. 2019 Nov;203:107391. doi: 10.1016/j.pharmthera.2019.07.002. Epub 2019 Jul 9.
Link
2258. GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer.
Park JE1, Jin MH1, Hur M2, Nam AR1, Bang JH1, Won J2, Oh DY3,4, Bang YJ1,5.
Gastric Cancer. 2019 Sep;22(5):932-940. doi: 10.1007/s10120-019-00943-x. Epub 2019 Feb 27.
Link
2257. Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study.
Kim JW1, Lee KH2,3, Kim JW1, Suh KJ1, Nam AR3, Bang JH3, Bang YJ2,3, Oh DY4,5.
Br J Cancer. 2019 Aug;121(4):332-339. doi: 10.1038/s41416-019-0523-5. Epub 2019 Jul 17.
Link
2256. Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer.
Park H1, Bang JH2, Nam AR2, Eun Park J2, Hua Jin M2, Bang YJ1,2, Oh DY3,4.
Sci Rep. 2019 Jul 31;9(1):11131. doi: 10.1038/s41598-019-47330-1.
Link